Retinal Vein Occlusion
Conditions
Brief summary
The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.
Interventions
Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO). RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
Sponsors
Regeneron Pharmaceuticals
Bayer
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female adult patients who suffer from visual impairment due to ME secondary to CRVO * Anti-VEGF treatment-naive patients who started reimbursed Eylea treatment between the 1st of June 2014 and the 28th of February 2015
Exclusion criteria
* Patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of eyes treated (mono-and biocular) | At 12 months of treatment with Eylea |
| Treatment duration | At 12 months of treatment with Eylea |
| Number of Eylea injections per treated eye | At 12 months of treatment with Eylea |
| Change in visual acuity (BCVA score) | At 12 months of treatment with Eylea |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients who discontinued their treatment with Eylea prematurely | At 12 months of treatment with Eylea | Investigator is asked to categorize the number of patients who ended their treatment prematurely according to the following reasons : * Lost-to-follow up (measured as number of patients) * Lack of efficacy (measured as number of patients) * Remission (measured as number of patients) * AE (measured as number of patients) * Other (measured as number of patients) |
| Estimation of percentage (%) of eyes which need additional treatment after 2 years at the discretion of the treating physician. | At 12 months of treatment with Eylea | — |
| Sufficiency of reimbursed number of Eylea injections (max. 9 injections/eye in year 1) for treatment of all patients during the first year of treatment. | At 12 months of treatment with Eylea | — |
Countries
Belgium
Outcome results
None listed